Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma

Comprehensive molecular characterization of gastric adenocarcinoma

(2014) Adam J. Bass et al.   NATURE

Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation

(2013) Eunice L. Kwak et al.   CANCER

Cyclin E1 Deregulation Occurs Early in Secretory Cell Transformation to Promote Formation of Fallopian Tube-Derived High-Grade Serous Ovarian Cancers

(2013) A. M. Karst et al.   CANCER RESEARCH

Monitoring Afatinib Treatment in HER2-Positive Gastric Cancer with 18F-FDG and 89Zr-Trastuzumab PET

(2013) Y. Y. Janjigian et al.   JOURNAL OF NUCLEAR MEDICINE

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

(2013) Tom Waddell et al.   LANCET ONCOLOGY

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

(2013) Florian Lordick et al.   LANCET ONCOLOGY

Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity

(2013) Austin M Dulak et al.   NATURE GENETICS

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma

(2013) S. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas

(2012) A Gallardo et al.   BRITISH JOURNAL OF CANCER

Regulation of ERBB2 Receptor by t-DARPP Mediates Trastuzumab Resistance in Human Esophageal Adenocarcinoma

(2012) J. Hong et al.   CANCER RESEARCH

Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis

(2012) A. M. Dulak et al.   CANCER RESEARCH

Clinical significance of intratumoral HER2 heterogeneity in gastric cancer

(2012) Hee Eun Lee et al.   EUROPEAN JOURNAL OF CANCER

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

(2012) Niantao Deng et al.   GUT

Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses

(2012) Elisabetta Kuhn et al.   JNCI-Journal of the National Cancer Institute

ErbB3 Inhibitory Surrobodies Inhibit Tumor Cell Proliferation In Vitro and In Vivo

(2012) P. K. Foreman et al.   MOLECULAR CANCER THERAPEUTICS

MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells

(2012) C.-T. Chen et al.   MOLECULAR CANCER THERAPEUTICS

Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification

(2012) W. Okamoto et al.   MOLECULAR CANCER THERAPEUTICS

Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

(2012) C. F. McDonagh et al.   MOLECULAR CANCER THERAPEUTICS

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

(2011) Leiping Wang et al.   BMC CANCER

Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

(2011) R. Ghosh et al.   CANCER RESEARCH

Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors

(2011) Luigi Aurisicchio et al.   JOURNAL OF CELLULAR PHYSIOLOGY

HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma

(2011) Yingchuan Hu et al.   MODERN PATHOLOGY

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

(2011) Siyuan Zhang et al.   NATURE MEDICINE

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+breast cancer patients

(2011) Maurizio Scaltriti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

(2011) J. T. Garrett et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing

(2011) Nikhil Wagle et al.   Cancer Discovery

High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability

(2011) Lydia W.T. Cheung et al.   Cancer Discovery

GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers

(2011) Craig H Mermel et al.   GENOME BIOLOGY

Global Patterns of Cancer Incidence and Mortality Rates and Trends

(2010) A. Jemal et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

EGFR/Ras/MAPK Signaling Mediates Adult Midgut Epithelial Homeostasis and Regeneration in Drosophila

(2010) Huaqi Jiang et al.   Cell Stem Cell

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

(2010) D. M. Hickinson et al.   CLINICAL CANCER RESEARCH

Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers

(2010) Bhuvanesh Dave et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance

(2009) Rajiv Dua et al.   BREAST CANCER RESEARCH AND TREATMENT

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

(2009) Teemu T. Junttila et al.   CANCER CELL

EGFR signaling regulates the proliferation of Drosophila adult midgut progenitors

(2009) H. Jiang et al.   DEVELOPMENT

A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy

(2008) S. T. Lee-Hoeflich et al.   CANCER RESEARCH

Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

(2008) P. J.A. Eichhorn et al.   CANCER RESEARCH